What does AI pharmaceuticals still lack before a market explosion? | Focus

① From the discovery of targets to the identification of preclinical candidate compounds, current generative AI mainly focuses on the early stages of drug development, which can lead to significant acceleration; ② If AI in drug development is to further expand the realm of possibilities, it must explore more profitable real-world applications.

cls.cnJan 19 19:34 ET

Zhaoke Ophthalmology Procures Distributor for Presbyopia Drug in Australia, New Zealand

MT NewswiresJan 13 07:16 ET

ZHAOKE OPHTH-B (06622.HK): A distribution agreement has been established with AFT PHARMACEUTICALS for the commercialization of BRIMOCHOL PF in Australia and New Zealand.

On January 13, Gelonghui reported that ZHAOKE OPHTH-B (06622.HK) announced that the company has signed a distribution and supply agreement with AFT Pharmaceuticals Limited ("AFT", a leading manufacturer and distributor of healthcare products based in New Zealand) for BRIMOCHOL PF ("the product"). BRIMOCHOL PF is a potential therapy for correcting near vision loss due to presbyopia. The company has discussed BRIMOCHOL PF with Tenpoint Therapeutics.

Gelonghui FinanceJan 13 04:45 ET

Express News | Zhaoke Ophthalmology Ltd - Entering Into Distribution- Agreement With AFT Pharmaceuticals

ReutersJan 13 04:41 ET

ZHAOKE OPHTH-B (6622.HK): The registration application for NVK002 has been formally accepted, further enhancing growth certainty.

Nowadays, the issue of myopia in children is becoming increasingly serious, and how to prevent and delay the development of myopia in children has become a focus of widespread attention among parents. As a result, various treatment methods have emerged in the market, and related discussions have become more intense. From traditional glasses to modern orthokeratology lenses and defocus lenses, as well as drug treatments, parents are urgently seeking suitable solutions for their children, hoping to find the safest and most effective way to delay myopia as soon as possible. Recently, Zhaoke Ophthalmology announced the simple new drug application for NVK002 (0.01% low-dose atropine), a medication used to control the progression of myopia in children, which has been officially accepted by the National Medical Products Administration. This means that

Gelonghui FinanceJan 6 20:32 ET

Selected Announcements | Alibaba's buyback plan still has a remaining amount of 20.7 billion USD; GTJA plans to conduct a stock swap to absorb and merge HAITONG SEC and will send a proposal to the meeting for fundraising support.

In 2024, Qinhuangdao Port's total throughput reached 0.414 billion tons, a year-on-year increase of 5.66%; ZHAOKE OPHTH-B: The National Medical Products Administration accepted the simplified new drug application for NVK002, used to treat worsening myopia in children.

cls.cnJan 2 19:11 ET

Zhitong Hong Kong stocks early news | China Securities Regulatory Commission: "The rumor that all Bearish will be released before January 15 is false". The S&P and Nasdaq recorded five consecutive declines.

China Securities Regulatory Commission: "Releasing all Bearish before January 15" and "Insurance companies large redemptions of public Funds" are both rumors.

Zhitong FinanceJan 2 18:28 ET

Express News | Zhaoke Ophthalmology - Nmpa Acceptance of Abbreviated New Drug- Application for Nvk002 for Treatment of- Myopia Progression in Children

ReutersJan 2 05:40 ET

Hong Kong stocks movement | ZHAOKE OPHTH-B (06622) once rose more than 8% as the drug for treating wet age-related macular degeneration reached the primary endpoint in its Phase III clinical trial.

ZHAOKE OPHTH-B (06622) once rose over 8%, as of the time of writing, it increased by 5.83%, priced at 1.27 Hong Kong dollars, with a transaction amount of 0.8308 million Hong Kong dollars.

Zhitong FinanceJan 1 21:56 ET

Zhao Ke Ophthalmology (06622): TAB014 related clinical trials have yielded positive results.

Kingwo Financial News | Zhaoke Ophthalmology (06622) announced that TAB014 (one of the company's core candidate drugs) has positive topline results from the Phase III clinical trial for the treatment of wet (neovascular) age-related macular degeneration (“wAMD”). This clinical trial successfully achieved the primary endpoint and key secondary endpoints. The Phase III clinical trial of TAB014 is a randomized, double-blind, and non-inferiority study, with the main objective of assessing the best corrected visual acuity (BCVA) at week 52 for the group receiving TAB014 treatment compared to the group receiving Lucentis treatment at baseline.

Jingu Finance News.Jan 1 20:08 ET

Zhaoke Ophthalmology-B (06622.HK): Latanoprost eye drops, Tafluprost eye drops, and Tafluprost nasal drops have been approved for marketing by the National Medical Products Administration.

On December 9, Gelonghui reported that Zhaoke Ophthalmology-B (06622.HK) announced that following the approval for marketing of Betamethasone Timolol Eye Drops and Bimatoprost Eye Drops, the company's glaucoma product portfolio has recently added three more pharmaceuticals (Latanoprost Eye Drops, Travoprost Eye Drops, and Travoprost Timolol Eye Drops) that have been approved for listing by the National Medical Products Administration ("NMPA"), equivalent to passing the consistency evaluation of generic drugs. These pharmaceuticals are all produced by the company. Together with Betamethasone Timolol Eye Drops and Bimatoprost Eye Drops, they constitute a comprehensive glaucoma product portfolio for managing intraocular pressure. The company believes its products...

Gelonghui FinanceDec 9, 2024 04:26 ET

Express News | Zhaoke Ophthalmology - Marketing Authorizations Obtained From Nmpa for Latanoprost Eye Drop, Travoprost Eye Drop, and Travoprost Timolol Eye Drop

ReutersDec 9, 2024 04:23 ET

Zhaoke Ophthalmology's Phase 3 Trial of Myopia Progression Drug Shows Positive Results

MT NewswiresOct 23, 2024 08:50 ET

China Medical Ophthalmology-B (06622.HK): The positive top-line results of the two-year China Phase III clinical trial (CHINA CHAMP) for NVK002, used to treat deepening myopia in children.

Oct 23, Geelong Health | Medigen Eye Care-B (06622.HK) announced that the topline results of the two-year Phase III clinical trial ("China CHAMP") of NVK002 (one of the company's core products) were released. After two years of treatment, the analysis of this study shows that the NVK002 eye drop group (0.01% and 0.02% doses) had statistically significant differences in the main efficacy indicators compared to the placebo group, with NVK002 eye drop group being superior to the placebo group and showing dose dependence. Both doses of NVK002 demonstrated good safety and patient compliance.

Gelonghui FinanceOct 23, 2024 05:48 ET

Zhaoke Ophthalmology Completes Last Patient Visit for Trial of Macular Degeneration Drug

MT NewswiresSep 26, 2024 06:01 ET

Chow's Ophthalmology-B (06622.HK): The final visit of the last patient in the TAB014 Phase III clinical trial was completed in China.

Glory9thdayTheMeanwhile,ZodiacEye-C(06622.HK)announced that TAB014(oneofthecompany'scorecandidateproperties)hascompletedthelastvisitforthelastpatientinPhaseIIIclinicaltrialfortreatingwet(neovascular)age-relatedmaculardegeneration('wAMD')onSeptember20,2024.Accordingtothedisclosure,TAB014PhaseIIIclinicaltrialisrandomized,double-blind,andnon-inferioritystudy.Theprimaryobjectiveofthestudyistoevaluate the best correction of the group receiving TAB014 treatment compared to the group receiving Lucentis treatment at week 52.

Gelonghui FinanceSep 26, 2024 04:33 ET

ZHAOKE OPHTH-B: 2024 Interim Report

HKEXSep 23, 2024 04:33 ET · Announcements

Zhaoke Ophthalmology Glaucoma Eye Drops Get Marketing Approval; Shares Rise 3%

MT NewswiresSep 19, 2024 22:28 ET

Chokesee Eye Care-B (06622.HK): Bemei Prostaglandin Eye Drops (Jingbeiqing) approved by the National Medical Products Administration for listing.

Gelonghui, September 20th | Mega Medical Ophthalmology-B (06622.HK) announced that the company's independently developed anti-glaucoma pharmaceutical Beimei Latanoprost Eye Drops (Crystal Bear Clear) has been approved for marketing by the National Medical Products Administration ("NMPA"). According to the disclosure, Beimei Latanoprost Eye Drops (Crystal Bear Clear) is China's first single-dose Latanoprost eye drops without preservatives, used to reduce intraocular pressure in patients with angle-closure glaucoma and high ocular pressure. This pharmaceutical does not contain preservatives, avoiding eye surface damage in glaucoma patients caused by long-term use of preservative-containing medications. At the same time, this medication also helps improve patients

Gelonghui FinanceSep 19, 2024 18:19 ET

Express News | Zhaoke Ophthalmology Ltd - Marketing Authorization for Bimatoprost Eye Drop (®) Obtained From Nmpa

ReutersSep 19, 2024 18:11 ET